No selective HDAC8 inhibitor has been approved as a drug, but a number of compounds described in the literature show promising activity against HDAC8; however, few of those compounds were assayed against cervical cancer, demanding additional efforts to comprehend the involvement of this isoform in cancer development using those cellular lineages (Banerjee et al., 2019). The gene discussed is HDAC8; the disease is cancer.